Price (delayed)
$1.24
Market cap
$88.24M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.75
Enterprise value
$69.74M
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2
There are no recent dividends present for VTYX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.